A unique sequence of the laminin alpha 3 G domain binds to heparin and promotes cell adhesion through syndecan-2 and -4.
Laminin-5, consisting of the alpha 3, beta 3, and gamma 2 chains, is localized in the skin basement membrane and supports the structural stability of the epidermo-dermal linkage and regulates various cellular functions. The alpha chains of laminins have been shown to have various biological activities. In this study, we identified a sequence of the alpha 3 chain C-terminal globular domain (LG1-LG5 modules) required for both heparin binding and cell adhesion using recombinant proteins and synthetic peptides. We found that the LG3 and LG4 modules have activity for heparin binding and that LG4 has activity for cell adhesion. Studies with synthetic peptides delineated the A3G75aR sequence (NSFMALYLSKGR, residues 1412--1423) within LG4 as a major site for both heparin and cell binding. Substitution mutations in LG4 and A3G75aR identified the Lys and Arg of the A3G75aR sequence as critical for these activities. Cell adhesion to LG4 and A3G75aR was inhibited by heparitinase I treatment of cells, suggesting that cell binding to the A3G75aR site was mediated by cell surface heparan sulfate proteoglycans. We showed by affinity chromatography that syndecan-2 from fibroblasts bound to LG4. Solid-phase assays confirmed that syndecan-2 interacted with the A3G75aR peptide sequence. Stably transfected 293T cells with expression vectors for syndecan-2 and -4, but not glypican-1, specifically adhered to LG4 and A3G75aR. These results indicate that the A3G75aR sequence within the laminin alpha 3 LG4 module is responsible for cell adhesion and suggest that syndecan-2 and -4 mediate this activity.
Utani
A
A
Department of Dermatology, School of Medicine, Chiba University, Chiba 260, Japan. Utani@derma01.m.chiba-u.ac.jp
Nomizu
M
M
Matsuura
H
H
Kato
K
K
Kobayashi
T
T
Takeda
U
U
Aota
S
S
Nielsen
P K
PK
Shinkai
H
H
D000906:Antibodies / Q000494:pharmacology; D001665:Binding Sites; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology*; D002460:Cell Line; D002478:Cells, Cultured; D005347:Fibroblasts / Q000166:cytology / Q000502:physiology*; D006025:Glycosaminoglycans / Q000494:pharmacology; D006493:Heparin / Q000378:metabolism*; D006801:Humans; D007231:Infant, Newborn; D015603:Keratinocytes / Q000502:physiology*; D007700:Kinetics; D007797:Laminin / Q000737:chemistry* / Q000378:metabolism*; D008562:Membrane Glycoproteins / Q000378:metabolism*; D008958:Models, Molecular; D009842:Oligopeptides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D010446:Peptide Fragments / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D011487:Protein Conformation; D017433:Protein Structure, Secondary; D011509:Proteoglycans / Q000378:metabolism*; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D012867:Skin / Q000166:cytology; D053669:Syndecan-2; D053671:Syndecan-4
D000906:Antibodies; D006025:Glycosaminoglycans; D007797:Laminin; D008562:Membrane Glycoproteins; D009842:Oligopeptides; D010446:Peptide Fragments; D011509:Proteoglycans; D011994:Recombinant Proteins; C508245:SDC2 protein, human; C508304:SDC4 protein, human; D053671:Syndecan-4; D053669:Syndecan-2; C095567:laminin alpha 3; D006493:Heparin